Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2336986. Online ahead of print.ABSTRACTINTRODUCTION: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injury. Until recently, no approved treatments were available for these patients.AREAS COVERED: Recent clinical trials for PFIC treatment have focused on intestine-restricted ileal bile acid transporter (IBAT) inhibitors. These compounds aim to reduce the pool size of bile acids by interrupting their enterohepatic circu...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Willemien F J Hof Jan Freark de Boer Henkjan J Verkade Source Type: research
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2331139. Online ahead of print.ABSTRACTINTRODUCTION: Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease.AREAS COVERED: We conducted a review analyzing literature from the PubMed database with the aim to describe the current state of art in the management of EGFR-mutated NSCLC, but also to explore new strategies under investigation. To this purpose, we collected recruiting phase II-III trials registere...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Valentina Favorito Ilaria Ricciotti Andrea De Giglio Laura Fabbri Renata Seminerio Alessandro Di Federico Eleonora Gariazzo Silvia Costabile Giulio Metro Source Type: research
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2336986. Online ahead of print.ABSTRACTINTRODUCTION: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injury. Until recently, no approved treatments were available for these patients.AREAS COVERED: Recent clinical trials for PFIC treatment have focused on intestine-restricted ileal bile acid transporter (IBAT) inhibitors. These compounds aim to reduce the pool size of bile acids by interrupting their enterohepatic circu...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Willemien F J Hof Jan Freark de Boer Henkjan J Verkade Source Type: research
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2331139. Online ahead of print.ABSTRACTINTRODUCTION: Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease.AREAS COVERED: We conducted a review analyzing literature from the PubMed database with the aim to describe the current state of art in the management of EGFR-mutated NSCLC, but also to explore new strategies under investigation. To this purpose, we collected recruiting phase II-III trials registere...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Valentina Favorito Ilaria Ricciotti Andrea De Giglio Laura Fabbri Renata Seminerio Alessandro Di Federico Eleonora Gariazzo Silvia Costabile Giulio Metro Source Type: research
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2336986. Online ahead of print.ABSTRACTINTRODUCTION: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injury. Until recently, no approved treatments were available for these patients.AREAS COVERED: Recent clinical trials for PFIC treatment have focused on intestine-restricted ileal bile acid transporter (IBAT) inhibitors. These compounds aim to reduce the pool size of bile acids by interrupting their enterohepatic circu...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Willemien F J Hof Jan Freark de Boer Henkjan J Verkade Source Type: research
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2331139. Online ahead of print.ABSTRACTINTRODUCTION: Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease.AREAS COVERED: We conducted a review analyzing literature from the PubMed database with the aim to describe the current state of art in the management of EGFR-mutated NSCLC, but also to explore new strategies under investigation. To this purpose, we collected recruiting phase II-III trials registere...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Valentina Favorito Ilaria Ricciotti Andrea De Giglio Laura Fabbri Renata Seminerio Alessandro Di Federico Eleonora Gariazzo Silvia Costabile Giulio Metro Source Type: research
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2336986. Online ahead of print.ABSTRACTINTRODUCTION: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injury. Until recently, no approved treatments were available for these patients.AREAS COVERED: Recent clinical trials for PFIC treatment have focused on intestine-restricted ileal bile acid transporter (IBAT) inhibitors. These compounds aim to reduce the pool size of bile acids by interrupting their enterohepatic circu...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Willemien F J Hof Jan Freark de Boer Henkjan J Verkade Source Type: research
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Expert Opin Emerg Drugs. 2024 Apr 4. doi: 10.1080/14728214.2024.2331139. Online ahead of print.ABSTRACTINTRODUCTION: Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease.AREAS COVERED: We conducted a review analyzing literature from the PubMed database with the aim to describe the current state of art in the management of EGFR-mutated NSCLC, but also to explore new strategies under investigation. To this purpose, we collected recruiting phase II-III trials registere...
Source: Expert Opinion on Emerging Drugs - April 4, 2024 Category: Drugs & Pharmacology Authors: Valentina Favorito Ilaria Ricciotti Andrea De Giglio Laura Fabbri Renata Seminerio Alessandro Di Federico Eleonora Gariazzo Silvia Costabile Giulio Metro Source Type: research
Emerging drugs for the treatment of sarcopenia in cirrhosis of the liver
Expert Opin Emerg Drugs. 2024 Mar 28:1-11. doi: 10.1080/14728214.2024.2332428. Online ahead of print.NO ABSTRACTPMID:38549232 | DOI:10.1080/14728214.2024.2332428 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - March 29, 2024 Category: Drugs & Pharmacology Authors: Simone Di Cola Saniya Khan Lucia Lapenna Manuela Merli Source Type: research
Evaluating emerging drugs in phase II & amp; III for the treatment of amyotrophic lateral sclerosis
Expert Opin Emerg Drugs. 2024 Mar 22:1-10. doi: 10.1080/14728214.2024.2333420. Online ahead of print.ABSTRACTINTRODUCTION: Amyotrophic Lateral Sclerosis is a rapidly progressive motor neuron disorder causing severe disability and premature death. Owing to the advances in uncovering ALS pathophysiology, efficient clinical trial design and research advocacy program, several disease-modifying drugs have been approved for treating ALS. Despite this progress, ALS remains a rapidly disabling and life shortening condition. There is a critical need for more effective therapies.AREAS COVERED: Here, we reviewed the emerging ALS ther...
Source: Expert Opinion on Emerging Drugs - March 22, 2024 Category: Drugs & Pharmacology Authors: Xiaoyan Li Richard Bedlack Source Type: research
